Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM
- 1 August 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (8), 1142-1152
- https://doi.org/10.1158/1541-7786.mcr-20-0024
Abstract
Epigenetic regulation known for DNA methylation and histone modification is critical for securing proper gene expression and chromosomal function, and its aberration induces various pathological conditions including cancer. Trimethylation of histone H3 on lysine 27 (H3K27me3) is known to suppress various genes related to cancer cell survival and the level of H3K27me3 may have an influence on tumor progression and malignancy. However, it remains unclear how histone methylation is regulated in response to genetic mutation and microenvironmental cues to facilitate the cancer cell survival. Here, we report a novel mechanism of the specific regulation of H3K27me3 by cooperatively two mechanistic target of rapamycin (mTOR) complexes, mTORC1 and mTORC2 in human glioblastoma (GBM). Integrated analyses revealed that mTORC1 upregulates the protein expression of enhancer of zeste homolog 2 (EZH2), a main component of polycomb repressive complex 2 (PRC2) which is known as H3K27-specific methyltransferase. The other mTOR complex, mTORC2, regulates production of S-adenosylmethionine (SAM), an essential substrate for histone methylation. This cooperative regulation causes H3K27 hypermethylation which subsequently promotes tumor cell survival both in vitro and in vivo xenografted mouse tumor model. These results indicate that activated mTORC1 and mTORC2 complexes cooperatively contribute to tumor progression through specific epigenetic regulation, nominating them as an exploitable therapeutic target against cancer. Implications: A dynamic regulation of histone methylation by mTOR complexes promotes tumor growth in human GBM, but at the same time could be exploitable as a novel therapeutic target against this deadly tumor.Keywords
Other Versions
Funding Information
- Japan Society for the Promotion of Science (19K07649)
- NIH (NS73831)
This publication has 52 references indexed in Scilit:
- The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expressionGenes & Development, 2013
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- The Polycomb complex PRC2 and its mark in lifeNature, 2011
- Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer CellsMolecular Cancer Research, 2010
- EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic TherapyScience Signaling, 2009
- Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancerBritish Journal of Surgery, 2009
- Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylationNature Genetics, 2008
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group SilencingScience, 2002